Elsevier's Biochimica et Biophysica Acta (BBA) Journal Series Adds Open Access Journal: BBA Clinical to its Portfolio

OXFORD, England, November 13, 2013 /PRNewswire/ --

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announces the launch of BBA Clinical, the first full open access journal within the Biochimica et Biophysica Acta (BBA) journal series. BBA Clinical will focus on translating molecular insights into clinical research.

BBA Clinical is a biomedical journal dedicated to publishing research on the molecular basis of human diseases, as well as presenting findings from clinical trials that target biochemical pathways and processes. All articles in BBA Clinical describe, in part or entirely, studies using human patient samples or human cohorts. Clinical areas of particular interest include aging, cancer, cardiovascular-, metabolic-, neurological-, and immunological diseases; the interactions that may occur among these different diseases and conditions; and studies that examine their early or pre-symptomatic states. Cross-sectional and prospective studies from well-established cohorts, and studies involving imaging methodologies, are particularly encouraged for submission.

"The journal provides a new forum for insights concerning the biochemical mechanisms related to diagnosis, progression, and treatment of a wide range of human diseases," said BBA Clinical Executive Editor, Jeffrey N. Keller from Pennington Biomedical Research Center, Baton Rouge, Louisiana. "BBA Clinical will offer not just a useful forum for clinical research today, but it is designed to be a prominent contributor to the larger overall body of clinical advancements far into the future."

"We are very excited about the launch of BBA Clinical," added Dolors Alsina, Executive Publisher at Elsevier. "The journal will build on our long standing track record as one of the leading international journals focusing on molecular aspects in biology and medicine and will break new ground as the clinical complement to BBA Molecular Basis of Disease."

For more information or to submit an article, go to http://www.journals.elsevier.com/bba-clinical

About Open Access Publishing at Elsevier

Elsevier has been providing open access publishing options since 2005. Today, researchers can choose to publish open access in over 1,600 established peer-reviewed journals as well as 67 full open access journals and these numbers will continue to grow rapidly. All of Elsevier's open access publications have been peer reviewed, ensuring that the broader community not only reads the latest research but that it is factual, original and of the highest quality and ethical standards. For more information about Elsevier's open access program, visit http://www.elsevier.com/openaccess

About Elsevier's Biochimica et Biophysica Acta (BBA) journal portfolio

BBA began publication in 1947. It was the first international journal dedicated to the publication of new findings from the emerging and synergistic fields of biochemistry and biophysics. Since that time, BBA has expanded to meet the needs of scientists focused on understanding the physics, molecular mechanisms, and biomedical underpinnings in diverse fields, including bioenergetics, proteomics, and lipid biology. Today BBA comprises ten different journals, each with unique editors and scope and an average impact factor above 5. The members of the American Library Association recognized BBA's outstanding value in 2009 by electing BBA to the 100 Most Influential Journals in Biology & Medicine over the last 100 years. http://www.elsevier.com/life-sciences/bba

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby's Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group PLC is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.

Media contact

Kristian Wilson
Elsevier
+44-186-584-3817
k.wilson@elsevier.com